Shares of ImmunoCellular Therapeutics Ltd. (OTC: IMUC), a development-stage company engaged in the development and commercialization of therapeutics to treat cancer using the immune system, rose sharply in Friday’s trading session.
The penny stock of IMUC ended the day 8.16% higher at $3.05.
Last Friday, IMUC said that it received approval for NYSE MKT listing. IMUC’s shares are expected to commence trading on NYSE MKT from tomorrow.
Commenting on the development, Manish Singh, Ph. D., president and CEO of ImmunoCellular Therapeutics, said that the listing marks an important step in IMUC’s development by giving the company access to a broader investor base and should provide increased transparency and liquidity for investors own IMUC’s common stock.
InvestorSoup.com is committed to provide intelligent commentary and solid analysis of small cap stocks, micro-cap stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily on the underserved OTC stocks market, or “penny stock” market, which has traditionally been shunned by Wall Street. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Neither InvestorSoup.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication.
The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. BeaconEquity.com is a wholly owned subsidiary of BlueWave Advisors, LLC.